Osprey Pharmaceuticals USA
Novel protein therapeutics for inflammatory and immune diseases
About Osprey Pharmaceuticals USA
Osprey Pharmaceuticals U.S.A., Inc. is a clinical-stage biopharmaceutical company focused on creating protein therapeutics to treat inflammatory and autoimmune conditions. Founded in 2008, the company operates as the U.S. arm to develop drugs emerging from its Canadian parent company, Osprey Pharmaceuticals Ltd. The firm is headquartered in San Francisco, California. The leadership team included Jack M. Anthony as Chief Executive Officer and Barbara K. Finck, M.D., as Chief Medical Officer.
The company's core technology revolves around its proprietary Leukocyte Population Modulators (LPMs), which are novel fusion protein therapeutics. These LPMs are engineered to selectively identify and eradicate disease-causing leukocytes by targeting the chemokine system, which regulates the movement and activity of these immune cells. This approach aims to neutralize chemokine-activated leukocytes that are responsible for initiating and perpetuating a variety of inflammatory and immune diseases.
Osprey’s lead product candidate, known as CCL2-LPM, is a therapeutic fusion protein designed to target the CCL2-CCR2 chemokine axis. This biological pathway is significant in conditions like inflammatory kidney diseases. In 2008, the company secured $11 million in its first venture capital funding round, led by Burrill & Company, to advance CCL2-LPM into clinical trials and further develop its LPM discovery platform. By 2025, total funding had reached $14.9 million over three rounds. The company's lead candidate entered a Phase Ib clinical trial for treating IgA nephropathy.
Source: Dealroom company dataNews
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES A✓Equity / VC | May 2009 | — | — | Undisclosed | — |
| DEBT✓Debt | May 2009 | $5.9M | — | Undisclosed | — |
Growth signals
Latest recorded traffic for Osprey Pharmaceuticals USA is 150 monthly website visits, up 0% over the last three months.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Osprey Pharmaceuticals USA in the San Francisco ecosystem
The Osprey Pharmaceuticals USA office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A4 investors entered at this stage
Western Technology Investment
Burrill- YDYasuda Enterprise Development
GeneChem
Series B and later1 investor entered at this stage
Ventures West
Other known investors2 additional known investors
BDC Capital
Novo Nordisk
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Osprey Pharmaceuticals USA on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Osprey Pharmaceuticals USA’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.






